Full Press Release Details
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
June 23, 2026
NXL Positive Sentiment Score: 75/100
Inside Nexalin: CEO Mark White on TBI Solutions & Expanding Market Potential
Key Takeaway: Nexalin Technology announced that the investigator of its Brazilian clinical trial received the Young Researcher Award at BRAIN 2026. This recognition underscores the significance of the company's proprietary DIFS™ platform in the field. The award reflects the promising advancements being made in the clinical trial.
Price reaction · baseline $3.46 (2025-02-18 close) · hit pre-market · clean, no other NXL news in the window
day 0 close · peak
-4.6%
Market Sentiment Analysis
POSITIVE FACTORS
- Nexalin's proprietary DIFS™ platform is gaining recognition.
- The Brazilian clinical trial is progressing well.
- The Young Researcher Award highlights the quality of research.
Frequently Asked Questions
What award did Nexalin's Brazilian trial investigator receive?
The investigator received the Young Researcher Award at BRAIN 2026.
What platform is Nexalin known for?
Nexalin is known for its proprietary DIFS™ platform.
What is the focus of Nexalin's clinical trial?
The clinical trial evaluates solutions for traumatic brain injury (TBI).
Who is the CEO of Nexalin Technology?
The CEO of Nexalin Technology is Mark White.